Dexa Group took part in the Pledge Ceremony for Pharmaceutical Industry Maturity, held by Indonesia’s National Agency for Drug and Food Control (BPOM). In his opening remarks, BPOM’s Chief, Mr. Taruna Ikrar, emphasized the agency’s commitment to strengthening compliance within the pharmaceutical industry with existing regulations and standards.

“Maturity is a process of growing into a more advanced state, reflected in all aspects of life. In the context of pharmaceutical industry maturity, considering the increasing challenges ahead, it is expected that Indonesia’s large pharmaceutical sector can reach higher levels and become ready for global markets,” stated Mr. Taruna at the event, which was held at Hotel JS Luwansa, South Jakarta, on Tuesday, September 24, 2024.

The event was attended by Dexa Group’s CEO Mr. Ferry Soetikno, President Director of PT Dexa Medica Mr. V Hery Sutanto, President Director of PT Ferron Par Pharmaceuticals Mr. Benny Sutisna Suwarno, and Dexa Group’s Quality Management Director Ms. Antonia Retno Tyas Utami. Also present were Mr. Tirto Kusnadi, Chairman of GP Farmasi, Mr. Elfiano Rizaldi, Executive Director of GP Farmasi, Ms. Rita Endang, Deputy for Drug, Narcotics, Psychotropics, Precursors, and Addictive Substances Control, and Mr. Sie Djohan, President Director of PT Kalbe Farma.

At the event, Dexa Group’s CEO, Mr. Ferry Soetikno, signed the Pledge to Enhance Pharmaceutical Industry Maturity in Indonesia: A Collaboration Toward Pharmaceutical Industry Independence for the Advancement and Competitiveness of Domestic Products. BPOM’s Chief, Kalbe Farma’s President Director, and GP Farmasi’s Chairman also signed this pledge.

“We appreciate BPOM’s initiative in organizing this pledge ceremony. This is a pivotal moment to enhance the competitiveness of the pharmaceutical industry,” said Mr. Ferry.

Echoing Mr. Ferry’s sentiment, Mr. V Hery reaffirmed Dexa Group’s commitment to continuously delivering high-quality products. “Dexa Group has greatly benefited from BPOM’s guidance and oversight. BPOM plays a crucial role in issuing Good Manufacturing Practice (GMP) certification,” stated Mr. Hery.

During the Focus Group Discussion session, Mr. Benny elaborated on Ferron’s journey since its founding, emphasizing the company’s ongoing commitment to quality. He stressed that quality must be systematically established.

“One key aspect is quality, which must be a priority. Quality does not happen on its own; it has to be built systematically,” said Mr. Benny.

At the same event, Ms. Dita Novianti, Director of Pharmaceutical Production and Distribution at the Ministry of Health, presented the government’s Health Transformation agenda, noting that pharmaceutical industry independence is part of the third pillar of this transformation.

BPOM Chief Visits Dexa Group Booth

Several pharmaceutical companies also set up booths during the event. Dexa Group showcased its Smart Pharma Factory 4.0 concept, which caught the attention of BPOM’s Chief, Mr. Taruna Ikrar.

During his visit to the Dexa Group booth, Mr. Taruna engaged in discussions with Mr. Ferry, Mr. Benny, and Mr. V Hery. Mr. Benny highlighted that Dexa Group’s products are now being exported to three continents and explained the implementation of the Quality System Maturity Model within Dexa Group.